San Francisco’s
life sciences industry,
in focus.

Nektar sold 4,062,500 shares of common stock in the offering, which includes 529,891 shares sold upon exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering.

The acquisition strengthens Servier’s leadership in low-grade glioma and expands the Group’s position in oncology with the addition of a marketed product and pipeline focused on rare cancers.

Terremoto Biosciences Raises $108M Series C for selective AKT1 therapies in oncology and rare disease

Spyre Therapeutics, Inc. (“Spyre” or the “Company”) announced the pricing of its previously announced underwritten public offering of 6,500,000 shares of its common stock at a price to the public of $62.00 per share.

Allogene Therapeutics, Inc. (Nasdaq: ALLO ) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $175 million of shares of its common stock.

Emerging biotechnology company aims to unlock targeting of disease-specific epigenetic protein interfaces to develop next‑generation therapies for pediatric cancers SAN FRANCISCO–(BUSINESS WIRE)–TippingPoint Biosciences today announced the closing of an oversubscribed $4.5 million seed financing to advance a breakthrough drug discovery platform that targets epigenetic protein interfaces long considered “undruggable,” opening a new frontier in precision medicine.

Aurinia Pharmaceuticals has entered into a definitive agreement to acquire Kezar Life Sciences.

Centivax, Inc., a clinical-stage biotechnology company engineering vaccines and therapies for durable, universal protection against highly diverse targets, announced the closing of a $37 million oversubscribed financing led by Structure Fund.

The San Francisco biotech announced a second seed round of $7.7 million USD, led by NFX – the venture firm behind Lyft, DoorDash, and Mammoth Biosciences, with over $1.5 billion USD under management – alongside One Way Ventures, M Ventures, Insight Partners, LongGame Ventures, T.Rx Capital, Healthspan Capital, Sand Hill Angels, and two independent investors.

$2 million upfront with up to approximately $4 million of potential aggregate gross proceeds upon the exercise in full of warrants BRISBANE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST ) (the “Company”), a clinical-stage biotechnology company...